As FAK inhibition has been demonstrated to reduce MCL-1 and BCL-XL expression, and synergistically induce apoptosis in AML when used alongside venetoclax, this combination could be an effective therapeutic strategy by both promoting apoptosis and inhibiting migration in CLL [48]. Here, PTK2 is linked to B-cell chronic lymphocytic leukemia.